Skip to main content
SpringerLink
Log in

A Risk-Benefit Assessment of Cisapride in the Treatment of Gastrointestinal Disorders

  • Review Article
  • Risk-Benefit Assessment
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Cisapride is a substituted benzamide compound that stimulates motor activity in all segments of the gastrointestinal tract by enhancing the release of acetylcholine from the enteric nervous system.

Cisapride is administered orally in the treatment of gastro-oesophageal reflux disease, functional dyspepsia, gastroparesis, chronic intestinal pseudo-obstruction syndromes and chronic constipation. In gastro-oesophageal reflux disease in both adults and children, cisapride provides symptomatic improvement and mucosal healing. Long term treatment with cisapride is effective in the prevention of relapse of oesophagitis. Cisapride improves gastric emptying rates and improves symptoms in patients with gastroparesis of various origins. Unlike domperidone and metoclopramide, long term administration of cisapride seems to result in persistently enhanced gastric emptying. Cisapride is also effective in improving symptoms in patients with functional dyspepsia. In comparative studies in patients with functional dyspepsia, cisapride was at least as effective as metoclopramide, domperidone, clebopride, ranitidine and cimetidine. Cisapride increases stool frequency and reduces laxative consumption in patients with idiopathic constipation. Severe cases of slow transit constipation seem refractory to cisapride. Clinical studies also indicate that cisapride might be effective in the treatment of chronic intestinal pseudo-obstruction, postoperative ileus, peptic ulcer and irritable bowel syndrome. Further clinical studies are warranted to define the role of cisapride in these conditions.

The dosage of cisapride ranges from 5mg 3 times daily to 20mg twice daily. Cisapride is generally well tolerated, both during short and long term treatment. In children, cisapride is also well tolerated in doses of 0.2 to 0.3 mg/kg, 3 to 4 times daily. The most frequently reported adverse effects are transient abdominal cramping, borborygmi and diarrhoea. These are an extension of the pharmacological profile of the drug and only rarely necessitate treatment withdrawal. Rarely, tachycardia and urinary disorders have been observed during treatment with cisapride. Unlike many other prokinetic agents, cisapride is devoid of central antidopaminergic and neuroendocrine effects. Hence, cisapride may be better tolerated than metoclopramide and domperidone. The acceleration of gastric emptying by cisapride may affect the absorption and peak plasma concentrations of other drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. McCallum RW, Prakath C, Campoli-Richards DM, et al. Cisapride: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a pro-kinetic agent in gastrointestinal motility disorders. Drugs 1988; 36: 652–81

    Article  PubMed  CAS  Google Scholar 

  2. Reyntjens AJ, Verlinden M, Schuurkes JAJ, et al. New approach to gastrointestinal motor dysfunction: non-antidopaminergic, non-cholinergic stimulation with cisapride. Curr Ther Res 1984; 36: 1045–52

    Google Scholar 

  3. Pfeuffer-Friederich I, Kilbinger H. Facilitation and inhibition by 5-hydroxytryptamine and R51619 of acetylcholine release from guinea pig myenteric neurones. In: Roman C, editor. Gastrointestinal motility. Lancaster: MTP Press, 1984: 527–34

    Chapter  Google Scholar 

  4. Nemeth PR, Ort CA, Zafirov DH, et al. Interactions between serotonin and cisapride on myenteric neurones. Eur J Pharmacol 1985; 166: 387–91

    Article  Google Scholar 

  5. Cohen ML, Bloomquist W, Gidda JS, et al. LY277359 maleate: a potent and selective 5-HT3 receptor antagonist without gastro-prokinetic activity. J Pharmacol Exp Ther 1990; 254: 350–5

    PubMed  CAS  Google Scholar 

  6. Dumuis A, Sebben M, Bockaert J. The gastrointestinal pro-kinetic benzamide derivatives are agonists at the non-classical 5-HT receptor (5-HT4) positively coupled to adenylate cyclase in neurons. Naunyn Schmiedebergs Arch Pharmacol 1989; 340: 403–10

    Article  PubMed  CAS  Google Scholar 

  7. Craig DA, Clarke DE. Pharmacological characterization of a neuronal receptor for 5-hydroxytryptamine in guinea pig ileum with properties similar to the 5-hydroxytryptamine4 receptor. J Pharmacol Exp Ther 1990; 252: 1378–86

    PubMed  CAS  Google Scholar 

  8. De Ridder WJE, Schuurkes JAJ. Cisapride and 5-hydroxytryptamine enhance motility in the canine antrum via separate pathways, not involving 5-hydroxytryptamine1,2,3,4 receptors. J Pharmacol Exp Ther 1993; 264: 79–88

    PubMed  Google Scholar 

  9. Wiseman LR, Faulds D. Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994; 47: 116–52

    Article  PubMed  CAS  Google Scholar 

  10. Corazziari E, Bontempo I, Anzini F. Effects of cisapride on distal esophageal motility in humans. Dig Dis Sci 1989; 34: 1600–5

    Article  PubMed  CAS  Google Scholar 

  11. Gilbert RJ, Dodds WJ, Kahrilas PJ, et al. Effect of cisapride, a new prokinetic agent, on esophageal motor function. Dig Dis Sci 1987; 32: 1331–6

    Article  PubMed  CAS  Google Scholar 

  12. Ceccatelli P, Janssens J, Vantrappen G. Cisapride restores the decreased lower esophageal sphincter pressure in reflux patients. Gut 1988; 29: 631–5

    Article  PubMed  CAS  Google Scholar 

  13. Wallin L, Kruse-Andersen A, Madsen T, et al. Effect of cisapride on the gastro-oesophageal function in normal human subjects. Digestion 1987; 37: 160–5

    Article  PubMed  CAS  Google Scholar 

  14. Wienbeck M, Li Q. Cisapride on gastro-oesophageal reflux disease: effects on oesophageal motility and intra-oesophageal pH. Scand J Gastroenterol 1989; 24 Suppl. 165: 13–8

    Article  Google Scholar 

  15. Holloway RH, Downton J, Mitchell B, et al. Effect of cisapride on postprandial gastro-oesophageal reflux. Gut 1989; 30: 1187–93

    Article  PubMed  CAS  Google Scholar 

  16. Marzio L, Grossi L, Alameddine M, et al. 48-Hour continuous pH measurement in patients with gastro-oesophageal reflux: effect of cisapride. Dig Dis Sci 1994; 37: 262–7

    Article  Google Scholar 

  17. Cucchiara S, Staiano A, Boccieri A, et al. Effects of cisapride on parameters of oesophageal motility and on the prolonged intraoesophageal pH test in infants with gastro-oesophageal reflux disease. Gut 1990; 31: 21–5

    Article  PubMed  CAS  Google Scholar 

  18. Brogna A, Ferrara R, Scornavacca G, et al. Cisapride and gastric emptying of a solid meal in dyspeptic patients without autonomic neuropathy and in healthy volunteers. Eur J Clin Pharmacol 1989; 37: 411–3

    Article  PubMed  CAS  Google Scholar 

  19. Fraser R, Horowitz M, Maddox A, et al. Dual effects of cisapride on gastric emptying and antropyloroduodenal motility. Am J Physiol 1993; 264: G195–G201

    PubMed  CAS  Google Scholar 

  20. Müller-Lisner SA, Fraas C, Haiti A. Cisapride offsets dopamine-induced slowing of fasting gastric emptying. Dig Dis Sci 1986; 31: 807–10

    Article  Google Scholar 

  21. Abell TL, Camilleri M, DiMagno EP, et al. Long-term efficacy of oral cisapride in symptomatic upper gut dysmotility. Dig Dis Sci 1991; 36: 616–20

    Article  PubMed  CAS  Google Scholar 

  22. Corinaldesi R, Stanghellini V, Raiti C, et al. Effect of chronic administration of cisapride on gastric emptying of a solid meal and on dyspeptic symptoms in patients with idiopathic gastroparesis. Gut 1987; 28: 300–5

    Article  PubMed  CAS  Google Scholar 

  23. Havelund T, Oster-Jorgensen E, Eshoj O, et al. Effect of cisapride on gastroparesis in patients with insulin-dependent diabetes mellitus: a double-blind controlled trial. Acta Med Scand 1987; 222: 339–43

    Article  PubMed  CAS  Google Scholar 

  24. Horowitz M, Maddox A, Harding PE, et al. Effect of cisapride on gastric and esophageal emptying in insulin-dependent diabetes mellitus. Gastroenterology 1987; 92: 1899–907

    PubMed  CAS  Google Scholar 

  25. Jian R, Ductor F, Ruskone A, et al. Symptomatic, radionuclide and therapeutic assessment of chronic idiopathic dyspepsia. A double-blind placebo-controlled evaluation of cisapride. Dig Dis Sci 1989; 34: 657–64

    Article  PubMed  CAS  Google Scholar 

  26. Richards RD, Valenzuela GA, Davenport KG, et al. Objective and subjective results of a randomised, double-blind, placebo-controlled trial using cisapride to treat gastroparesis. Dig Dis Sci 1993; 38: 811–6

    Article  PubMed  CAS  Google Scholar 

  27. Stacher G, Abatzi-Wenzel TA, Wiesnagrotzki S, et al. Gastric emptying, body weight and symptoms in primary anorexia nervosa. Br J Psychiatry 1993; 162: 398–402

    Article  PubMed  CAS  Google Scholar 

  28. Urbain JLC, Siegel JA, Debien C, et al. Effect of cisapride on gastric emptying in dyspeptic patients. Dig Dis Sci 1988; 33: 779–83

    Article  PubMed  CAS  Google Scholar 

  29. Feldman M, Smith HJ. Effect of cisapride on gastric emptying of indigestible solids in patients with gastroparesis diabeticorum. A comparison with metoclopramide and placebo. Gastroenterology 1987; 92: 171–4

    PubMed  CAS  Google Scholar 

  30. Carroccio A, Iacono G, Li Voti G, et al. Gastric emptying in infants with gastroesophageal reflux. Ultrasound evaluation before and after cisapride administration. Scand J Gastroenterol 1992; 27: 799–804

    Article  PubMed  CAS  Google Scholar 

  31. Wehrmann T, Lembcke B, Caspary WF. Influence of cisapride on antroduodenal motor function in healthy subjects and diabetics with autonomic neuropathy. Aliment Pharmacol Ther 1991; 5: 599–608

    Article  PubMed  CAS  Google Scholar 

  32. Coremans G, Chaussade S, Janssens J, et al. Stimulation of propulsive motility patterns by cisapride in the upper gut of man. Dig Dis Sci 1985; 30: 765

    Google Scholar 

  33. Edwards CA, Holden S, Brown C, et al. Effect of cisapride on the gastrointestinal transit of a solid meal in normal human subjects. Gut 1987; 28: 13–6

    Article  PubMed  CAS  Google Scholar 

  34. Krevsky B, Malmud LS, Maurer A, et al. The effect of oral cisapride on colonic transit. Aliment Pharmacol Ther 1987; 1: 293–304

    Article  PubMed  CAS  Google Scholar 

  35. Müller-Lisner SA, and the Bavarian Constipation Study Group. Cisapride in chronic idiopathic constipation: can the colon be re-educated? Eur J Gastroenterol Hepatol 1995; 7: 69–73

    Google Scholar 

  36. Müller-Lisner SA, and the Bavarian Constipation Study group. Treatment of chronic constipation with cisapride and placebo. Gut 1987; 28: 1033–8

    Article  Google Scholar 

  37. Enck P, Apring HG, Engel S, et al. Effects of cisapride on anorectal sphincter function. Aliment Pharmacol Ther 1989; 3: 539–45

    Article  PubMed  CAS  Google Scholar 

  38. Dakkak M, Jones BP, Scott MGB, et al. Comparing the efficacy of cisapride and ranitidine in oesophagitis: a double-blind, parallel group study in general practice. Br J Clin Pract 1994; 48: 10–4

    PubMed  CAS  Google Scholar 

  39. Galmiche JP, Fraitag B, Filoche B, et al. Double-blind comparison of cisapride and cimetidine in treatment of reflux esophagitis. Dig Dis Sci 1990; 35: 649–55

    Article  PubMed  CAS  Google Scholar 

  40. Galmiche JP, Brandstõtter G, Evreux M, et al. Combined therapy with cisapride and cimetidine in severe reflux esophagitis. Dig Dis Sci 1988; 35: 675–81

    Google Scholar 

  41. Blum AL, Adami B, Bouzo MH, et al. Effect of cisapride on relapse of esophagitis. Dig Dis Sci 1993; 38: 551–60

    Article  PubMed  CAS  Google Scholar 

  42. Toussaint J, Gossuin A, Deruyterre M, et al. Healing and prevention of relapse of reflux oesophagitis by cisapride. Gut 1991; 32: 1280–5

    Article  PubMed  CAS  Google Scholar 

  43. Tytgat GNJ, Anker Hansen OJ, Carling L, et al. Effect of cisapride on relapse of reflux oesophagitis, healed with an antisecretory drug. Scand J Gastroenterol 1992; 27: 175–83

    Article  PubMed  CAS  Google Scholar 

  44. Greally P, Hampton FJ, MacFadyen UM, et al. Gaviscon and carobel compared with cisapride in gastro-oesophageal reflux. Arch Dis Child 1992; 67: 618–21

    Article  PubMed  CAS  Google Scholar 

  45. De Caestecker JS, Ewing DJ, Tothill P, et al. Evaluation of oral cisapride and metoclopramide in diabetic autonomic neuropathy: an eight-week double-blind crossover study. Aliment Pharmacol Ther 1989; 3: 69–81

    Article  PubMed  Google Scholar 

  46. Dworkin BM, Rosenthal WS, Casellas AR, et al. Open label study of long-term effectiveness of cisapride in patients with idiopathic gastroparesis. Dig Dis Sci 1994; 39: 1395–8

    Article  PubMed  CAS  Google Scholar 

  47. Horowitz M, Harding PE, Chatterton BE, et al. Acute and chronic effects of domperidone on gastric emptying in diabetic autonomic neuropathy. Dig Dis Sci 1985; 30: 1–9

    Article  PubMed  CAS  Google Scholar 

  48. Schade RR, Dugas MC, Lhotsky DM, et al. Effect of metoclopramide on gastric liquid emptying in patients with diabetic gastroparesis. Dig Dis Sci 1985; 30: 10–5

    Article  PubMed  CAS  Google Scholar 

  49. Horowitz M, Roberts P. Long-term efficacy of cisapride in diabetic gastroparesis. Am J Med 1990; 88: 195–6

    Article  PubMed  CAS  Google Scholar 

  50. Camilleri M, Malagelada JR, Abell TL, et al. Effect of six weeks’ treatment with cisapride in gastroparesis and intestinal pseudo-obstruction. Gastroenterology 1989; 96: 704–12

    PubMed  CAS  Google Scholar 

  51. Agorastos I, Akriviadis E, Goulis G. Effect of cisapride in non-ulcer dyspepsia. A placebo-controlled trial. Curr Ther Res 1991; 49: 870–7

    Google Scholar 

  52. Hausken T, Berstad A. Cisapride treatment of patients with non-ulcer dyspepsia and erosive prepyloric changes. Scand J Gastroenterol 1992; 27: 213–7

    Article  PubMed  CAS  Google Scholar 

  53. Wood SF, Penney SC, Cochran KM. Cisapride in functional dyspepsia: a double-blind placebo-controlled randomised trial in general practice patients. Scand J Gastroenterol 1993; 28 Suppl. 195: 5–10

    Article  Google Scholar 

  54. Marzio L, DiFelice F, Laico MG, et al. Gallbladder hypokinesia and normal gastric emptying of liquids in patients with dyspeptic symptoms. A double-blind placebo-controlled trial with cisapride. Dig Dis Sci 1992; 37: 262–7

    Article  PubMed  CAS  Google Scholar 

  55. Cucchiara S, Bortolotti M, Minella R, et al. Children with functional gastrointestinal symptoms: effects of cisapride on fasting antroduodenal motility, gastric emptying of liquids and symptoms. Eur J Gastroenterol Hepatol 1992; 4: 627–33

    Google Scholar 

  56. Heyse PM, Rambaldo R, Hazelhoff B. Factors affecting short- and long-term outcome of a short therapeutic trial with cisapride in dyspeptic patients. Scand J Gastroenterol 1993; 28 Suppl. 195: 15–24

    Article  Google Scholar 

  57. Inoue M, Sekiguchi T, Harasawa S, et al. Dyspepsia and dyspepsia subgroups in Japan: symptom profiles and experience with cisapride. Scand J Gastroenterol 1993; 28 Suppl. 195: 36–9

    Article  Google Scholar 

  58. Archimandritis A, Tzivras M, Fertakis A, et al. Cisapride, metoclopramide and ranitidine in the treatment of severe nonulcer dyspepsia. Clin Ther 1992; 14: 553–61

    PubMed  CAS  Google Scholar 

  59. Halter F, Miazza B, Brignoli R. Cisapride or cimetidine in the treatment of functional dyspepsia. Scand J Gastroenterol 1994; 29: 618–23

    Article  PubMed  CAS  Google Scholar 

  60. Sabbatini F, Minieri M, Manzi G, et al. Clinical efficacy and safety of cisapride and clebopride in the management of chronic functional dyspepsia. A double-blind, randomized study. Ital J Gastroenterol 1991; 23: 1–4

    PubMed  CAS  Google Scholar 

  61. Van Outryve M, De Nutte N, Van Eeghem P, et al. Efficacy of cisapride in functional dyspepsia resistant to domperidone or metoclopramide: a double-blind, placebo-controlled study. Scand J Gastroenterol 1993; 28 Suppl. 195: 47–53

    Article  Google Scholar 

  62. Hernandez G, Troncoso G, Palencia C, et al. Double-blind dose response study of cisapride in the treatment of chronic functional constipation. Adv Ther 1988; 5: 121–7

    Google Scholar 

  63. Verheyen K, Vervaeke M, Demyttenaere P, et al. Double blind comparison of two cisapride dosage regimens with placebo in the treatment of functional constipation. Curr Ther Res 1987; 41: 978–85

    Google Scholar 

  64. Coremans G, Vantrappen G. Does cisapride improve longstanding intractable constipation? Digestion 1986; 24: 137–60

    Google Scholar 

  65. Staiano A, Cucchiara S, Andreotti MR, et al. Effect of cisapride on chronic idiopathic constipation in children. Dig Dis Sci 1991; 36: 733–6

    Article  PubMed  CAS  Google Scholar 

  66. deGroot GH, dePagter GF. Effects of cisapride on constipation due to a neurological lesion. Paraplegia 1988; 26: 159–61

    Article  CAS  Google Scholar 

  67. Etienne M, Verlinden M, Brassinne A. Treatment with cisapride of the gastrointestinal and urological sequelae of spinal cord transection: case report. Paraplegia 1988; 26: 162–4

    Article  PubMed  CAS  Google Scholar 

  68. Hellstrom PM, Aly A, Johansson C. Cisapride stimulates small intestinal motility and relieves constipation in myelopathy due to cervical spinal stenosis: case report. Paraplegia 1990; 28: 261–4

    Article  PubMed  CAS  Google Scholar 

  69. Camilleri M, Brown ML, Malagelada JR. Impaired transit of chyme in chronic intestinal pseudo-obstruction: correction by cisapride. Gastroenterology 1986; 91: 619–26

    PubMed  CAS  Google Scholar 

  70. Cohen NP, Booth IW, Parashar K, et al. Successful management of idiopathic intestinal pseudo-obstruction with cisapride. J Pediatr Surg 1988; 23: 229–30

    Article  PubMed  CAS  Google Scholar 

  71. Fraser AG, Arthur JF, Hamilton I. Intestinal pseudoobstruction secondary to amyloidosis responsive to cisapride. Dig Dis Sci 1991; 36: 532–5

    Article  PubMed  CAS  Google Scholar 

  72. Baechle JP, Le Manach YL, Pitti R, et al. Traitement de la pseudo-occlusion colique aigue (syndrome d’Ogilvie) par le cisapride. Ann Fr Anesth Reanim 1994; 13: 248–50

    Article  PubMed  CAS  Google Scholar 

  73. Bourhis F, Rolachon A, Bost R, et al. Pseudo-obstruction colique aigue (syndrome d’Ogilvie): traitement par le cisapride. Gastroenterol Clin Biol 1991; 15: 559–60

    PubMed  CAS  Google Scholar 

  74. McColl C, McCannell KL, Baylis B, et al. Treatment of acute colonic pseudo-obstruction (Ogilvie’s syndrome) with cisapride. Gastroenterology 1990; 98: 773–6

    Google Scholar 

  75. Bogaert A, Haesert G, Mourisse P, et al. Placebo controlled trial of cisapride in postoperative ileus. Acta Anesthesiol Belg 1987; 38: 195–9

    Google Scholar 

  76. Benson MJ, Roberts JP, Wingate DL, et al. Small bowel motility following major intra-abdominal surgery: the effects of opiates and rectal cisapride. Gastroenterology 1994; 106: 924–36

    PubMed  CAS  Google Scholar 

  77. Tollesson PO, Cassuto J, Rimback G, et al. Treatment of postoperative ileus with cisapride. Scand J Gastroenterol 1991; 26: 477–82

    Article  PubMed  CAS  Google Scholar 

  78. Clevers GJ, Hendriks AV, Smout AJPM, et al. Prospective double-blind placebo-controlled study on the effect of cisapride on early postoperative nausea and vomiting. Surg Res Commun 1991; 10: 45–50

    Google Scholar 

  79. Van der Mijle HC, Beekhuis H, Bleichrodt RP, et al. Cisapride in the treatment of Roux-en-Y syndrome. Dig Dis Sci 1991; 36: 1691–6

    Article  PubMed  Google Scholar 

  80. Bouzo H. Cisapride in the postcholecystectomy syndrome. A double-blind, placebo-controlled, crossover study. Curr Ther Res 1990; 47: 566–70

    Google Scholar 

  81. Farup PG, Tjora S, Tholfsen JK. Effect of cisapride on symptoms and biliary drainage in patients with postcholecystectomy syndrome. Scand J Gastroenterol 1991; 26: 945–50

    Article  PubMed  CAS  Google Scholar 

  82. Van Outryve M, Milo R, Toussaint J, et al. Prokinetic treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride. J Clin Gastroenterol 1991; 13: 49–57

    Article  PubMed  Google Scholar 

  83. Testoni PA, Bagnolo F, Masci E, et al. Efficacy of cisapride in gastric ulcer: results of a double-blind randomized trial versus ranitidine and versus cisapride plus ranitidine. J Clin Gastroenterol 1993; 17: 5–9

    Article  PubMed  CAS  Google Scholar 

  84. Kerrigan DD, Taylor ME, Read NW, et al. Acid, motility and ulcers: a comparison of cisapride with placebo in the prevention of duodenal ulcer relapse. Gut 1993; 34: 1042–6

    Article  PubMed  CAS  Google Scholar 

  85. Van Peer A, Verlinden M, Woestenborghs R, et al. Clinical pharmacokinetics of cisapride. In: Johnson AG, Lux G, editors. Progress in the treatment of gastrointestinal motility disorders: the role of cisapride. Amsterdam: Excerpta Medica, 1988: 23–9

    Google Scholar 

  86. Gladziwa U, Bares R, Klotz U, et al. Pharmacokinetics and pharmacodynamics of cisapride in patients undergoing hemodialysis. Clin Pharmacol Ther 1991; 50: 673–81

    Article  PubMed  CAS  Google Scholar 

  87. Verlinden M, Reyntjens A, Schuermans V. Safety profile of cisapride. In: Johnson AG, Lux G, editors. Progress in the treatment of gastrointestinal motility disorders: the role of cisapride. Amsterdam: Excerpta Medica, 1988: 30–6

    Google Scholar 

  88. Fehr HE Risk factors, co-medication and concomitant diseases: their influence on the outcome of therapy with cisapride. Scand J Gastroenterol 1993; 28 Suppl. 195: 40–6

    Google Scholar 

  89. Martignoni E, Facchinetti F, Comitini G, et al. Cisapride (R 51619) has no effect on anterior pituitary secretions. Neuroendocrinol Lett 1986; 9: 57–61

    Google Scholar 

  90. Rocco A, Falashi P, Aversa A, et al. Prolactin response to a single oral administration of cisapride and clebopride in normal males. Neuroendocrinol Lett 1993; 12: 373–81

    Google Scholar 

  91. Kaumann AJ. Do human atrial 5-HT4 receptors mediate arrhythmias? Trends Pharmacol Sci 1994; 15: 451–5

    Article  PubMed  CAS  Google Scholar 

  92. Olsson S, Edwards IR. Tachycardia during cisapride treatment. BMJ 1992; 305: 748–9

    Article  PubMed  CAS  Google Scholar 

  93. Bateman DN. The action of cisapride on gastric emptying and the pharmacodynamics and pharmacokinetics of oral diazepam. Eur J Clin Pharmacol 1986; 30: 205–8

    Article  PubMed  CAS  Google Scholar 

  94. Humphrey PPA, Bunce KT. Tachycardia during cisapride treatment. BMJ 1992; 305: 1019–20

    Article  PubMed  CAS  Google Scholar 

  95. Inman W, Kubota K. Tachycardia during cisapride treatment. BMJ 1992; 305: 1019

    Article  PubMed  CAS  Google Scholar 

  96. Boyd IW, Rohan AP. Urinary disorders associated with cisapride. Med J Aust 1994; 160: 579–80

    PubMed  CAS  Google Scholar 

  97. Arabehety JT, Leitao OR, Fassler S, et al. Cisapride and metoclopramide in the treatment of gastroesophageal reflux disease. Clin Ther 1988; 10: 421–8

    PubMed  CAS  Google Scholar 

  98. Kirch W, Janisch HD, Ohnhaus EE, et al. Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption. Ther Drug Monit 1989; 11: 411–4

    PubMed  CAS  Google Scholar 

  99. Kuroda T, Yoshihara Y, Nakamura H, et al. Effects of cisapride on gastrointestinal motor activity and gastric emptying of disopyramide. J Pharmacobio Dynamics 1992; 15: 395–402

    Article  CAS  Google Scholar 

  100. Rowbotham DJ, Milligan K, McHugh P. Effect of single doses of cisapride and ranitidine administered simultaneously on plasma concentrations of cisapride and ranitidine. Br J Anaesth 1991; 67: 302–5

    Article  PubMed  CAS  Google Scholar 

  101. Roine R, Heikkonen E, Salaspuro M. Cisapride enhances alcohol absorption and leads to high blood alcohol levels. Gastroenterology 1992; 102: A507

    Google Scholar 

  102. Rowbotham DJ, Milligan K, McHugh P. Effect of cisapride on morphine absorption after oral administration of sustained-release morphine. Br J Anaesth 1991; 67: 421–5

    Article  PubMed  CAS  Google Scholar 

  103. Davies DS, Mills FJ, Welburn PJ. Cisapride has no effect on antipyrine clearance. Br J Pharmacol 1988; 26: 808–9

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine and Division of Gastroenterology, University Hospital Gasthuisberg, University of Leuven, Herestraat 49, B-3000, Leuven, Belgium

    Jan Tack, George Coremans & Jozef Janssens

Authors
  1. Jan Tack
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George Coremans
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jozef Janssens
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tack, J., Coremans, G. & Janssens, J. A Risk-Benefit Assessment of Cisapride in the Treatment of Gastrointestinal Disorders. Drug-Safety 12, 384–392 (1995). https://doi.org/10.2165/00002018-199512060-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199512060-00004

Keywords

Search

Navigation